Impact of Severe Tricuspid Regurgitation Correction on Gut Microbiota and Gastrointestinal Function
Launched by FRANCESCO MAISANO · Mar 24, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients, able to sign the Informed Consent Form, admitted to OSR Heart Valve Center with TR ≥ severe treated with T-TEER.
- Exclusion Criteria:
- • Concomitant ≥ severe MR. Such patients may be treated with M-TEER and be re-evaluated after 3 months: if TR is ≥ severe and MR is ≤ moderate the patient may then be enrolled.
- • Surgical candidates
- • Recent \< 6 months cardiac coronary or structural procedure
- • CAD requiring intervention
- • other valvular disease \> moderate
- • Treatment with transcatheter tricuspid replacement
- • Age \<18 years
- • Inability or unwillingness to sign informed consent
- • Kidney dialysis
- • Acute infection
- • Inflammatory bowel diseases
- • Gastrointestinal diseases
- • Previous gastrointestinal surgery
- • Active cancer
- • Active autoimmune or inflammatory diseases
- • Treatments with antibiotics or probiotics within one month
- • Emergency procedures
- • Patients enrolled in interventional studies that may confound study results
About Francesco Maisano
Francesco Maisano is a distinguished clinical trial sponsor with a commitment to advancing medical research and innovation. With extensive expertise in the field, he oversees the design and implementation of clinical studies aimed at evaluating new therapies and interventions. His leadership is characterized by a strong emphasis on ethical standards, regulatory compliance, and patient safety, ensuring that all trials are conducted with the highest integrity. Under his guidance, the organization strives to foster collaboration among research teams, healthcare professionals, and stakeholders, ultimately contributing to the enhancement of patient care and outcomes in various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milano, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported